Nuvectis Pharma, Inc. NVCT

Rank #2409 · Nasdaq · $0.5B market cap

Audited by PricewaterhouseCoopers International Limited, no going-concern flag in the latest filing.

Score

20.2

P/E

-25.8

P/B

40.18

ROE

-155.7%

Op. Margin

–%

Debt Ratio

73%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -25.8x, P/B 40.18x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -155.7%. Ranks in the top 96% of the universe.

Safety ★★★☆☆

Good

Debt ratio 73%. Ranks in the top 31% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2022	–	$-0.0B	$-0.0B	$-0.0B	–	-24190
2023	–	$-0.0B	$-0.0B	$-0.0B	–	-56
2024	–	$-0.0B	$-0.0B	$0.0B	–	49
2025	–	$-0.0B	$-0.0B	$0.0B	–	73